KRISHNA MOHAN VADREVU,VENKATA CHERISH BADU PELLURI,KHAJESH SHARMA
申请号：
MX2012014051
公开号：
MX2012014051A
申请日:
2010.07.14
申请国别(地区):
MX
年份:
2013
代理人:
摘要：
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition, also comprise base ingredients, carriers, preservatives, emulsifiers, skin. emollients and soothers and one or more other constituents. The novel composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.Se describe una composición farmacéutica sinergística novedosa para la preparación de formulaciones tópicas para la profilaxis y el tratamiento de heridas, heridas por quemaduras, injertos de piel, úlceras de presión y úlceras de pie diabético. La composición siriergística comprende una proteína mitógena en combinación con uno o más agentes bactericidas y bacteriostáticos. La proteína mitógena de la invención es el factor de crecimiento epidérmico humano recombinante (rh-EGF de Bharat Biotech International Limited) y/o cualquier otro factor de crecimiento como el rh-PDGF-BB, y los agentes bactericidas y bacteriostáticos son los antibióticos de amplio
